Fibrates, glitazones, and peroxisome ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Title :
Fibrates, glitazones, and peroxisome proliferator-activated receptors.
Author(s) :
Lalloyer, Fanny [Auteur]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Staels, Bart [Auteur correspondant]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Staels, Bart [Auteur correspondant]
Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 [RNMCD]
Journal title :
Arteriosclerosis, Thrombosis, and Vascular Biology
Pages :
894-9
Publisher :
American Heart Association
Publication date :
2010-05
ISSN :
1079-5642
HAL domain(s) :
Sciences du Vivant [q-bio]/Biochimie, Biologie Moléculaire
English abstract : [en]
Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of ...
Show more >Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.Show less >
Show more >Several decades ago, fibrates were approved for the treatment of dyslipidemia, whereas thiazolidinediones were screened in animal models to improve glucose homeostasis and were subsequently developed for the treatment of type 2 diabetes mellitus. Relatively recently, these drugs were found to act via peroxisome proliferator-activated receptors, nuclear receptors that control lipid metabolism and glucose homeostasis. In this historical perspective, we discuss the history of discovery of the peroxisome proliferator-activated receptors, from the clinical development of their agonists to the subsequent discovery of these receptors and their mechanisms of action, to finally evoke possibilities of targeted pharmacology for future development of selective peroxisome proliferator-activated receptor modulators.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Source :
Files
- https://www.hal.inserm.fr/inserm-00475566/document
- Open access
- Access the document
- https://www.hal.inserm.fr/inserm-00475566/file/LalloyerStaels_HistoryPPARs.pdf
- Open access
- Access the document
- https://www.hal.inserm.fr/inserm-00475566/document
- Open access
- Access the document
- https://www.hal.inserm.fr/inserm-00475566/document
- Open access
- Access the document
- inserm-00475566_edited.pdf
- Open access
- Access the document
- LalloyerStaels_HistoryPPARs.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- document
- Open access
- Access the document
- inserm-00475566_edited.pdf
- Open access
- Access the document
- LalloyerStaels_HistoryPPARs.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- inserm-00475566_edited.pdf
- Open access
- Access the document
- LalloyerStaels_HistoryPPARs.pdf
- Open access
- Access the document